Key features and details
- Rabbit polyclonal to CYP4V2
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-CYP4V2 antibody
See all CYP4V2 primary antibodies
DescriptionRabbit polyclonal to CYP4V2
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Orangutan
Recombinant fragment corresponding to Human CYP4V2 aa 246-525.
LMFKEGWEHKKSLQILHTFTNSVIAERANEMNANEDCRGDGRGSAPSKNK RRAFLDLLLSVTDDEGNRLSHEDIREEVDTFMFEGHDTTAAAINWSLYLL GSNPEVQKKVDHELDDVFGKSDRPATVEDLKKLRYLECVIKETLRLFPSV PLFARSVSEDCEVAGYRVLKGTEAVIIPYALHRDPRYFPNPEEFQPERFF PENAQGRHPYAYVPFSAGPRNCIGQKFAVMEEKTILSCILRHFWIESNQK REELGLEGQLILRPSNGIWIKLKRRNADER
Database link: Q6ZWL3-1
- WB: Jurkat whole cell lysate (ab7899). IHC-P: Human kidney tissue.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol (glycerin, glycerine), PBS
Concentration information loading...
Our Abpromise guarantee covers the use of ab224742 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/5000.|
|IHC-P||1/20 - 1/200.|
FunctionCatalyzes the omega-hydroxylation of medium-chain saturated fatty acids such as laurate, myristate and palmitate in an NADPH-dependent pathway. The substrate specificity is higher for myristate > laurate > palmitate (C14>C16>C12). May have a role in fatty acid and steroid metabolism in the eye.
Tissue specificityBroadly expressed. Detected in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, retina, retinal pigment epithelium (RPE) and lymphocytes.
Involvement in diseaseBietti crystalline corneoretinal dystrophy (BCD) [MIM:210370]: An autosomal recessive ocular disease characterized by retinal degeneration and marginal corneal dystrophy. Typical features include multiple glistening intraretinal crystals scattered over the fundus, a characteristic degeneration of the retina, and sclerosis of the choroidal vessels, ultimately resulting in progressive night blindness and constriction of the visual field. Most patients have similar crystals at the corneoscleral limbus. Patients develop decreased vision, nyctalopia, and paracentral scotomata between the 2nd and 4th decade of life. Later, they develop peripheral visual field loss and marked visual impairment, usually progressing to legal blindness by the 5th or 6th decade of life. Note=The disease is caused by mutations affecting the gene represented in this entry.
Sequence similaritiesBelongs to the cytochrome P450 family.
Cellular localizationEndoplasmic reticulum membrane.
- Information by UniProt
- BCD antibody
- CP4V2_HUMAN antibody
- CYP4AH1 antibody
Paraffin embedded human kidney tissue stained for CYP4V2 with ab224742 (1/100 dilution) in immunohistochemical analysis.
Anti-CYP4V2 antibody (ab224742) at 1/1000 dilution + Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate
Goat polyclonal to rabbit at 1/10000 dilution
Developed using the ECL technique.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab224742 has not yet been referenced specifically in any publications.